Jul 6 2010
Hard to Treat Diseases, Inc. (HTDS; http://www.htdsmedical.com) and Shenzhen Mellow Hope (www.mellowhope.com) are excited to announce that the company has secured a new business partner in Ethiopia through which Mellow Hope will distribute biomedical vaccines.
"We anticipate that our new Ethiopian partner will provide Mellow Hope with more business opportunities in that country, which will certainly improve the company's annual performance," said Terry Yuan, president of HTDS. "Furthermore, it is our hope that this partnership will be only the beginning in the expansion of HTDS and Mellow Hope vaccinations into other African markets."
China's trade in biomedical vaccines increased 20% between 2008 and 2009. At the same time, thanks to China's competitive pricing, trade between China and African countries has increased more than sevenfold since 2000. With diseases like H1N1, SARS, and avian flu requiring widespread immunization, the global vaccine market is expected to grow 18% annually to a value of $300 billion USD in 2011.
Shenzhen Mellow Hope specializes in biological vaccines such as influenza, Hepatitis A & B, and Meningococcal Polysaccharide.